Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2005
09/22/2005CA2564614A1 Combinatorial interleukin-2 muteins
09/22/2005CA2560212A1 Compositions comprising organometallic molybdenum compounds for treating cancer
09/22/2005CA2560046A1 Methods for suppressing tumor proliferation
09/22/2005CA2559172A1 Therapeutic use of rm1 antigen
09/22/2005CA2558632A1 Improved interleukin-2 muteins
09/22/2005CA2557005A1 Antineoplastic combinations of cci-779 and rituximab
09/21/2005EP1577387A1 Preventives/remedies for cancer
09/21/2005EP1577383A1 Novel adaptor protein binding to mammalian toll-like receptor 3 and gene thereof
09/21/2005EP1577323A1 Metastin derivative and use thereof
09/21/2005EP1577322A1 Novel proteins and use thereof
09/21/2005EP1577315A1 Process for producing hop glume polyphenol
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576966A1 Method of preparing a vaccine and anti-tumor vaccines
09/21/2005EP1576964A1 Protease inhibitor
09/21/2005EP1576959A1 A coixenolide capsules for treating prostate disease
09/21/2005EP1576958A1 An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof
09/21/2005EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines
09/21/2005EP1576179A2 Methods and compositions for inducing apoptosis in cancer cells
09/21/2005EP1576169A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/21/2005EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use
09/21/2005EP1576160A2 Borrelidin-producing polyketide synthase and its use
09/21/2005EP1576159A1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
09/21/2005EP1576156A1 Dec-205 (ly 75) / dcl-1 intergenic splice variants associated with hodkin's disease, and uses thereof
09/21/2005EP1576150A2 Methods and compositions for increasing the efficacy of biologically-active ingredients
09/21/2005EP1576119A2 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
09/21/2005EP1576110A2 Cell migration inhibiting compositions and methods and compositions for treating cancer
09/21/2005EP1576090A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
09/21/2005EP1576088A2 Dominant negative proteins and methods thereof
09/21/2005EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/21/2005EP1576010A2 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
09/21/2005EP1575993A2 Methods for treating patients and identifying therapeutics
09/21/2005EP1575984A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
09/21/2005EP1575976A2 Methods and compositions for therapeutic use of rna interference
09/21/2005EP1575973A2 Substitution derivatives of n sp 6 sp -benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
09/21/2005EP1575966A1 Therapeutic quinazoline derivatives
09/21/2005EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
09/21/2005EP1575963A1 Therapeutic agents
09/21/2005EP1575955A1 Pyrrolobenzodiazepines
09/21/2005EP1575954A2 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
09/21/2005EP1575947A1 2-oxopyridin-3-yl thia(di)azole derivatives for use in the treatment of cell proliferation and apoptosis related diseases
09/21/2005EP1575946A1 Quinazoline compounds
09/21/2005EP1575943A1 3-cyano-quinoline derivatives
09/21/2005EP1575940A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
09/21/2005EP1575933A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
09/21/2005EP1575916A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
09/21/2005EP1575673A2 Use of a trpm8-activating substance for the treatment of tumours
09/21/2005EP1575672A2 Use of cd137 antagonists for the treatment of tumors
09/21/2005EP1575592A1 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
09/21/2005EP1575591A1 Heterocycles and uses thereof
09/21/2005EP1575580A2 Method of treating cancers
09/21/2005EP1575579A2 Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents
09/21/2005EP1575571A2 Compositions and methods for the diagnosis and treatment of tumor
09/21/2005EP1575552A2 Metal-containing materials, compositions and methods
09/21/2005EP1575524A2 Proliferated cell lines and uses thereof
09/21/2005EP1575512A2 Methods and compositions for prostate epithelial cell differentiation
09/21/2005EP1575509A2 Epha2 agonistic monoclonal antibodies and methods of use thereof
09/21/2005EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
09/21/2005EP1575491A2 Treatment of renal carcinoma using antibodies against the egfr
09/21/2005EP1575414A2 Methods and devices for detection and therapy of atheromatous plaque
09/21/2005EP1435965A4 Pharmaceutical compositions and methods for treating cancer
09/21/2005EP1404377B1 Improved chelator conjugates
09/21/2005EP1294679B1 Beta-amino acid nitrile derivatives
09/21/2005EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists
09/21/2005EP1263446B1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
09/21/2005EP1220857B1 Gonadotropin releasing hormone receptor antagonists and their related methods of use
09/21/2005EP1140091B1 Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
09/21/2005EP1137640B1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
09/21/2005EP1129188B1 Pge synthase and methods and means for modulating its activity
09/21/2005EP1061805B1 Regulation of endogenous gene expression in cells using zinc finger proteins
09/21/2005EP0959881B1 Synthetic methods for the preparation of indolylquinones and mono- and bis-indolylquinones prepared therefrom
09/21/2005EP0793721B1 Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
09/21/2005CN1671863A Central airway administration for systemic delivery of therapeutics
09/21/2005CN1671856A Novel physiologically active substances
09/21/2005CN1671851A Flavivirus vaccine delivery system
09/21/2005CN1671837A Neutralizing human anti-IGFR antibody
09/21/2005CN1671744A Low molecular weight oversulfated polysaccharide
09/21/2005CN1671741A Buffered formulations for concentrating antibodies and methods of use thereof
09/21/2005CN1671733A Compositions and methods for WT1 specific immunotherapy
09/21/2005CN1671730A Oligonucleotide-containing pharmacological compositions and their use
09/21/2005CN1671723A Novel difluorinated gem compounds, preparation methods thereof and applications of same
09/21/2005CN1671715A Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
09/21/2005CN1671714A Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
09/21/2005CN1671701A Novel aryllimidazole derivatives, preparation and therapeutic used thereof
09/21/2005CN1671700A Substituted alkylamine derivatives and methods of use
09/21/2005CN1671696A 激酶抑制剂 Kinase inhibitors
09/21/2005CN1671694A Bisindolyl-maleimid derivatives as kinase inhibitors
09/21/2005CN1671666A Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
09/21/2005CN1671660A 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composi
09/21/2005CN1671644A Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA-damaging treatments
09/21/2005CN1671423A Novel chimeric CD154
09/21/2005CN1671415A Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
09/21/2005CN1671414A CpG formulations and related methods
09/21/2005CN1671397A Use of alkyl phosphocholines in combination with antitumor medicaments
09/21/2005CN1671395A Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol
09/21/2005CN1671391A Novel methods and compositions for alleviating pain
09/21/2005CN1671390A Adenosine A2A receptor antagonists for treating restless legs syndrome or related disorders
09/21/2005CN1671389A 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
09/21/2005CN1671385A Parenteral formulations containing a rapamycin hydroxyester
09/21/2005CN1671379A Hydrazonopyrazole derivatives and their use as therapeutics
09/21/2005CN1671378A Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
1 ... 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 ... 2211